In re: Prothena Corporation PLC Securities Litigation

Track this case

Case Number:

1:18-cv-06425

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Andrew L. Carter, Jr

Firms

Companies

Sectors & Industries:

  1. October 29, 2019

    Labaton, Levi & Korsinsky Seek $4.7M Fees For Prothena Suit

    Prothena investors urged a New York federal court Monday to grant their attorneys at Labaton Sucharow LLP and Levi & Korsinsky LLP $4.7 million in fees and give the final go-ahead to a $15.75 million deal with the biotechnology company, resolving securities fraud claims over a clinical trial.

  2. August 27, 2019

    Prothena Settles Stock-Drop Suit For $15.75M

    Prothena investors have negotiated a $15.75 million settlement with the neuroscience research and development company, which would end claims that it hid salient details of a clinical trial for a new drug and hurt shareholders when revelations about the trial made its stock price fall by nearly 70%.

  3. September 18, 2018

    Labaton, Levi Vie For Lead Role In Prothena Stock-Drop Row

    Labaton Sucharow LLP and Levi & Korsinsky LLP threw their hats in the ring to be co-lead counsel in a proposed securities class action alleging Prothena cherry-picked drug trial results and lost investors more than $2 million, according to a Monday filing in New York federal court.